Juvenile Rheumatoid Arthritis News and Research

RSS

Juvenile rheumatoid arthritis (JRA) is a severe autoimmune disorder that causes both painful and disabling arthritis and ocular manifestations which can result in blindness.

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

Abbott has announced that it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.

26 Feb 2008

Enbrel shown to significantly reduced levels of C-reactive protein

Amgen and Wyeth Pharmaceuticals, a division of Wyeth have announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment. Median reduction in CRP levels was 10 times greater in the ENBREL treated group compared to the placebo treated group.

5 Feb 2008

Discovery of gene variant that increases risk for Crohn's disease

Pediatrics researchers have identified a gene variant that raises a child's risk of Crohn's disease, a chronic and painful condition attributed to inflammation of the gastrointestinal tract.

19 Jul 2007

New gene found for type 1 diabetes in children

Pediatrics researchers at The Children's Hospital of Philadelphia and McGill University in Montreal have identified a gene variant that raises a child's risk for type 1 diabetes, formerly called juvenile diabetes.

16 Jul 2007

Enbrel safety data for up to 8 years in patients with juvenile rheumatoid arthritis

Amgen and Wyeth Pharmaceuticals, a division of Wyeth have announced the presentation of additional data that showed that the safety profile of Enbrel, (etanercept) was maintained with long-term use in patients with moderate-to-severe juvenile rheumatoid arthritis (JRA) who completed up to eight years of therapy.

17 Jun 2007

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Abbott has announced it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the U.S. and juvenile idiopathic arthritis (JIA) in the European Union (EU).

9 May 2007

Abbott opens biotech facility in Puerto Rico

"This new facility is a key milestone for Abbott as we move to focus our resources and future growth on biologic and potent-drug manufacturing," said Lawrence Kraus, vice president of manufacturing, global pharmaceutical operations, Abbott.

11 Apr 2007

Health disparities in juvenile rheumatoid arthritis

Juvenile rheumatoid arthritis (JRA), a group of autoimmune diseases involving chronic inflammation of the joints, can adversely affect health-related quality of life, often into adulthood.

31 May 2006

$Childhood arthritis increases the risk of fractures$

Childhood arthritis increases the risk of fractures

Childhood arthritis increases the risk of fractures, particularly during adolescence, according to a large study of British patient records. The researchers say that more targeted treatments promoting bone health would benefit patients with childhood-onset arthritis throughout their lifespan.

8 May 2006

Specific guidelines for treating juvenile idiopathic arthritis

A study published by the Cleveland Clinic and The Hospital for Sick Children (SickKids) provides the medical community for the first time with specific guidelines for treating juvenile idiopathic arthritis (JIA), previously known as juvenile rheumatoid arthritis (JRA), a condition that affects approximately one in every 1,000 children.

4 Oct 2005

Arthritis medications (methotrexate and leflunomide) commonly used in adults are safe and effective in children

An international team of researchers, led by Dr. Earl Silverman of The Hospital for Sick Children (Sick Kids), has found that two arthritis medications (methotrexate and leflunomide) commonly used in adults are safe and effective in children. This research is reported in the April 21, 2005 issue of The New England Journal of Medicine.

20 Apr 2005

Trial of Etanercept for Wegners's disease shows no benefit against the autoimmune condition

A Johns Hopkins-led study designed to evaluate the ability of etanercept to maintain disease remissions in a serious autoimmune disorder has failed to show any benefit. Etanercept, also called Enbrel, is a common treatment for rheumatoid arthritis and other types of joint inflammation.

26 Jan 2005

Shortage of pediatric rheumatologists often leads to improper diagnosis and treatment

More than 150,000 children in the United States are affected by rheumatic diseases such as juvenile rheumatoid arthritis, lupus, dermatomyositis, scleroderma, and systemic vasculitis.

10 Oct 2004

Children who take steroid drugs for nephrotic syndrome do not suffer bone loss

Childhood nephrotic syndrome, which affects 3 out of 100,000 children, is the most common chronic kidney disease in children. Although it does not impair kidney function, it weakens the body's ability to remove water and salt from the blood, and causes swelling in the belly, legs, and around the eyes.

25 Aug 2004